<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098600</url>
  </required_header>
  <id_info>
    <org_study_id>NKS1001</org_study_id>
    <nct_id>NCT05098600</nct_id>
  </id_info>
  <brief_title>The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic</brief_title>
  <official_title>The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculty Hospital Kralovske Vinohrady</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculty Hospital Kralovske Vinohrady</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study series consists of two studies with the aim to assess the incidence, prevalence,&#xD;
      risk factors, comorbidities and management of patients with alopecia areata in Czech Republic&#xD;
      based on the registry of a dermatology clinic of a metropolitan hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first study will aim to identify the epidemiology of alopecia areata in the dermatology&#xD;
      clinic of a metropolitan teaching hospital and the variety of treatments used in our clinic&#xD;
      between 1/1/2011 and 31/12/2020&#xD;
&#xD;
      The second study will assess (1) the epidemiology of autoimmune diseases and other conditions&#xD;
      in patients with alopecia areata, (2) the presence of possible risk factors responsible for&#xD;
      the onset/relapse/exacerbation of alopecia areata and (3) the variety, duration, efficacy and&#xD;
      safety profile of treatment modalities used in our hospital for the management of alopecia&#xD;
      areata from 1/10/2020 to 30/9/2021.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">January 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The epidemiology of Alopecia areata</measure>
    <time_frame>1/1/2010-31/12/2020</time_frame>
    <description>The incidence and point prevalence of Alopecia areata within the study cohort during the study period, stratified by age-group and gender</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The epidemiology of Alopecia areata</measure>
    <time_frame>1/10/2020-30/9/2021</time_frame>
    <description>The incidence and point prevalence of Alopecia areata (totalis, universalis, ophiasis, sisaipho, reticularis, diffuse, barbae) within the study cohort during the study period, stratified by age-group and gender</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of atopic and autoimmune conditions in patients with Alopecia Areata</measure>
    <time_frame>1/10/2020-30/9/2021</time_frame>
    <description>Prevalence of atopic and autoimmune conditions in patients with Alopecia Areata</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatments for alopecia areata</measure>
    <time_frame>1/1/2010-31/12/2020</time_frame>
    <description>Assessment of various treatment modalities used for alopecia areata</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and efficacy of treatments in alopecia areata</measure>
    <time_frame>1/10/2020-30/9/2021</time_frame>
    <description>Assessment of various treatment modalities used for alopecia areata, efficacy, duration of treatment, reported side-effects and relapse rate after withdrawal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of atopic and autoimmune conditions in the family history of patients with Alopecia Areata</measure>
    <time_frame>1/10/2020-30/9/2021</time_frame>
    <description>Prevalence of atopic and autoimmune conditions in parents and siblings of patients with Alopecia Areata</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification and prevalence of possible exacerbating factors in patients with Alopecia Areata</measure>
    <time_frame>1/10/2020-30/9/2021</time_frame>
    <description>Identification of possible risk factors occuring within 6 months from the onset/relapse/worsening of alopecia areata, according to patient history</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Alopecia Areata</condition>
  <condition>Alopecia Totalis</condition>
  <condition>Alopecia Universalis</condition>
  <condition>Alopecia Areata (&amp; Ophiasis)</condition>
  <condition>Alopecia Barbae</condition>
  <condition>Alopecia Diffuse</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Autoimmune Hyperthyroidism</condition>
  <condition>Autoimmune Hypothyroidism</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Crohn Disease</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Down Syndrome</condition>
  <condition>Atopic Dermatitis</condition>
  <condition>Atopic Asthma</condition>
  <condition>Atopic Rhinitis</condition>
  <condition>Vitiligo</condition>
  <condition>Psoriasis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Lupus Erythematosus</condition>
  <condition>COVID-19 Pandemic</condition>
  <condition>Vaccine Reaction</condition>
  <condition>Infections</condition>
  <condition>Anemia, Pernicious</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients with a confirmed histologic/dermatoscopic diagnosis of Alopecia areata within the study period will be included for analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure of interest</intervention_name>
    <description>Common autoimmune and atopic conditions consist of atopic dermatitis, allergic rhinitis, asthma, Crohn's disease, ulcerative colitis, Celiac disease, Pernicious anaemia, Type 1 diabetes, Autoimmune thyroiditis (Hashimoto's thyroiditis, Grave's disease, atrophic, unspecified), rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, Systemic lupus erythematosus, Sjogren syndrome, psoriasis, vitiligo, Multiple sclerosis</description>
    <arm_group_label>Cases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult and children patients with a dermatologic condition between 1/1/2010-31/12/2020 and&#xD;
        for the second study, adults and children with first-onset/relasping/worsening/ or&#xD;
        under-treament alopecia areata who sign informed consent are eligible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients visiting our clinic with a dermatologic condition between&#xD;
             1/1/2010-31/12/2020&#xD;
&#xD;
          -  For the second study, only patients with histologic/dermatoscopic diagnosis of&#xD;
             alopecia areata, presenting to our clinic between 1/10/2020-30/9/2021 are included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For the second study, patients with other alopecias, patients denying data sharing&#xD;
             despite signing the informed concent and presenting outside the study period are&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Teaching Hospital of Royal Vineguards</name>
      <address>
        <city>Prague</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <results_reference>
    <citation>Harries M, Macbeth AE, Holmes S, Chiu WS, Gallardo WR, Nijher M, de Lusignan S, Tziotzios C, Messenger AG. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2021 Jul 6. doi: 10.1111/bjd.20628. [Epub ahead of print]</citation>
    <PMID>34227101</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 16, 2021</study_first_submitted>
  <study_first_submitted_qc>October 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculty Hospital Kralovske Vinohrady</investigator_affiliation>
    <investigator_full_name>Athanasios J. Stefanis</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Graves Disease</mesh_term>
    <mesh_term>Anemia, Pernicious</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
    <mesh_term>Vitiligo</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
    <mesh_term>Hyperthyroidism</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

